Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma.

Tumor lysis syndrome is a potentially lethal complication of chemotherapy, usually associated with aggressive hematologic malignancies. We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1-2 weeks while being treated. Copyright © 2018 King Faisal Specialist Hospital & Research Centre. All rights reserved.

Citation

Sardar Zakariya Imam, Mohammad Faizan Zahid, Muhammad Asad Maqbool. Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma. Hematology/oncology and stem cell therapy. 2020 Sep;13(3):168-170

Mesh Tags

Substances

PMID: 29684339

search → result